Phuong D, Pirtz M, Ralston C, Cosgrove B, Schimenti J, Flesken-Nikitin A
Cancers (Basel). 2025; 17(4).
PMID: 40002199
PMC: 11852459.
DOI: 10.3390/cancers17040604.
Flesken-Nikitin A, Ralston C, Fu D, De Micheli A, Phuong D, Harlan B
Nat Commun. 2024; 15(1):8641.
PMID: 39366996
PMC: 11452611.
DOI: 10.1038/s41467-024-52984-1.
Pote M, Singh D, M A A, Suchita J, Gacche R
Heliyon. 2024; 10(15):e35369.
PMID: 39170575
PMC: 11336595.
DOI: 10.1016/j.heliyon.2024.e35369.
Wang Y, Duval A, Adli M, Matei D
J Clin Invest. 2024; 134(1).
PMID: 38165032
PMC: 10760962.
DOI: 10.1172/JCI174013.
Arnaoutoglou C, Dampala K, Anthoulakis C, Papanikolaou E, Tentas I, Dragoutsos G
Medicina (Kaunas). 2023; 59(7).
PMID: 37511995
PMC: 10384230.
DOI: 10.3390/medicina59071183.
The Validation of a Precursor Lesion of Epithelial Ovarian Cancer in KO Mice.
Sczelecki S, Pitman J
Cancers (Basel). 2023; 15(9).
PMID: 37174061
PMC: 10177028.
DOI: 10.3390/cancers15092595.
Assessing the roles of collagen fiber morphology and matrix stiffness on ovarian cancer cell migration dynamics using multiphoton fabricated orthogonal image-based models.
Alkmin S, Patankar M, Campagnola P
Acta Biomater. 2022; 153:342-354.
PMID: 36152908
PMC: 10324295.
DOI: 10.1016/j.actbio.2022.09.037.
Harnessing preclinical models for the interrogation of ovarian cancer.
Qin T, Fan J, Lu F, Zhang L, Liu C, Xiong Q
J Exp Clin Cancer Res. 2022; 41(1):277.
PMID: 36114548
PMC: 9479310.
DOI: 10.1186/s13046-022-02486-z.
Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.
Zhang X, Kong W, Gao M, Huang W, Peng C, Huang Z
J Cell Mol Med. 2022; 26(13):3659-3674.
PMID: 35735060
PMC: 9258710.
DOI: 10.1111/jcmm.17360.
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D
Cell Mol Life Sci. 2022; 79(7):364.
PMID: 35705879
PMC: 9200670.
DOI: 10.1007/s00018-022-04395-y.
USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
Kwon J, Choi H, Ware A, Morillo B, Wang H, Bouker K
Oncogene. 2022; 41(13):1974-1985.
PMID: 35173307
PMC: 8956511.
DOI: 10.1038/s41388-022-02224-x.
Oncogenic Events Dictate the Types and Locations of Gynecological Malignancies Originating from Mesothelial and Müllerian-Derived Epithelial Cells.
Park E, Xiang D, Xie Y, Bronson R, Li Z
Cancers (Basel). 2022; 14(3).
PMID: 35159108
PMC: 8834519.
DOI: 10.3390/cancers14030841.
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.
Liu C, Barger C, Karpf A
Cancers (Basel). 2021; 13(12).
PMID: 34205406
PMC: 8235333.
DOI: 10.3390/cancers13123065.
Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
Yang W, Kim D, Kim D, Choi K, Suh D, Kim J
Int J Mol Sci. 2021; 22(10).
PMID: 34064635
PMC: 8151268.
DOI: 10.3390/ijms22105059.
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer I, Lundberg M, Demicco E, Przybyl J, Matusiak M, Chibon F
Cancer. 2021; 127(15):2666-2673.
PMID: 33788262
PMC: 8277678.
DOI: 10.1002/cncr.33542.
Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis.
Mei J, Tian H, Huang H, Hsu C, Liou Y, Wu N
Cell Prolif. 2021; 54(5):e13029.
PMID: 33768671
PMC: 8088460.
DOI: 10.1111/cpr.13029.
Mouse models of epithelial ovarian cancer for preclinical studies.
Karakashev S, Zhang R
Zool Res. 2021; 42(2):153-160.
PMID: 33527800
PMC: 7995272.
DOI: 10.24272/j.issn.2095-8137.2020.382.
Acidochromic Behavior of Dibenzylidene Cyclohexanone-Based Bischalcone: Experimental and Theoretical Study.
Rahman Badal M, Ashekul Islam H, Maniruzzaman M, Abu Yousuf M
ACS Omega. 2020; 5(36):22978-22983.
PMID: 32954147
PMC: 7495756.
DOI: 10.1021/acsomega.0c02556.
Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches.
Zakarya R, Howell V, Colvin E
Int J Mol Sci. 2020; 21(13).
PMID: 32645943
PMC: 7370285.
DOI: 10.3390/ijms21134806.
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Brandon A, Box G, Hallsworth A, Court W, Matthews N, Herodek B
Sci Rep. 2020; 10(1):10799.
PMID: 32612269
PMC: 7329846.
DOI: 10.1038/s41598-020-67533-1.